compound pharmacy bpc 157 This is the first vote from the FDA's Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the FDA will make BPC-157 (10mg) for Research |

Research Verdict: When to Use Each or Both Choose BPC-157 When Research Focuses On: Gastrointestinal healing and protection Tendon and ligament injuries Nerve regeneration and neuroprotection Situations requiring oral administration Protection from NSAID or other toxic damage Choose TB-500 When Research Focuses On: Cardiac tissue repair and cardioprotection Wound healing and scar reduction Systemic anti-inflammatory effects Muscle regeneration Hair follicle research Consider Combination When: Comprehensive tissue repair is the goal (e.g., complex injury involving multiple tissue types) Maximizing angiogenesis AND cell migration is desired Research hypothesis involves sequential healing phases Mechanistic Rationale for Stacking: The combination addresses different phases of healingBPC-157 promotes blood vessel ingrowth and initial cytoprotection, while TB-500 facilitates the cellular repair and remodeling that follows vascularization

6 weeks: 3 vials use 6 mL total

It is not FDA-approved for general therapeutic use in humans, and the World Anti-Doping Agency added it to its Prohibited List in 2022

The source matters significantly for results

Quality sourcing becomes critical for both routes but especially important for injectable preparations requiring sterile handling